Safety data from those trials was published Monday in the journal JAMA Neurology in a study whose authors included eight Biogen employees.The data showed that 425 of 1,029 patients, or 41 percent, who received the high dose of the drug — the dose that the F.D.A. later approved — experienced either brain swelling or bleeding….
